COMMUNIQUÉS West-GlobeNewswire

-
Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
04/06/2018 -
Cesca Therapeutics Announces Reduction in Operating Expenses
04/06/2018 -
Viveve Announces Settlement of Patent Infringement Litigation with Thermi
04/06/2018 -
Evolus to Present at the Jefferies 2018 Global Healthcare Conference
04/06/2018 -
Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)
04/06/2018 -
DBV Technologies : Correctif - Assemblée Générale Mixte du 22 juin 2018 - Modalités de mise à disposition des documents préparatoires à l'Assemblée
04/06/2018 -
Athenex Names Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific
04/06/2018 -
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics
04/06/2018 -
Checkpoint Therapeutics to Participate in June Investor Conferences
04/06/2018 -
Soleno Therapeutics To Present Corporate Update at the BIO International Convention
04/06/2018 -
Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
04/06/2018 -
Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
04/06/2018 -
Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
04/06/2018 -
Novo Nordisk A/S - Share repurchase programme
04/06/2018 -
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253
04/06/2018 -
Avalon GloboCare Appoints Former Deputy Secretary of the U.S. Department of Health and Human Services Dr. Tevi Troy to its Board of Directors
04/06/2018 -
NexoBrid® Receives Marketing Authorization From South Korea’s Ministry of Health
04/06/2018 -
Assembly Biosciences to Participate in Jefferies 2018 Global Healthcare Conference
04/06/2018 -
Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions
04/06/2018
Pages